🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Standing ovation for a very poignant and just beautiful opening session by Eric J. Small, MD, FASCO Dr. Lynn Schuchter “The art & science of cancer care: from comfort to cure”—it is all about our patients. ASCO #ASCO24

Happening now! @DrGattiMays discussing new and upcoming data for breast cancer treatment with Oncology Brothers #bcsm

G Curigliano MD PhD: DB06 novel LBA session #ASCO24. 60% in TPC received cape. Med FU 18 mo. 3% bone only. Most CDKi preTx. PFS HR 0.62 HER2 low. OS early. Ultralow HR 0.78 w/wide CI overlap 1. 2+ > 1+. ORR better! Grade 5 ILD 0.7%. New SOC 4 hi risk/visc Mets in HER2 low. OncoAlert

.Maryam Lustberg MD, MPH, FASCO co-chairs the Bernard Fisher Memorial Annual Clinical Science Symposium sponsored by The Breast Cancer Research Foundation with Dr. Manali Bhave Winship Cancer Institute of Emory University on the Emerging Role of ctDNA in #breastcancer at #ASCO24. YaleBreastCancer Smilow Cancer Hospital Yale School of Medicine

Great discussion on #ctDNA by Daniel Stover, MD, FASCO! Sensitivity matters in #ctDNA detection! Liquid biopsy is not there yet to replace tissue biopsy! Need more studies to validate results! The James Ohio State Medical Oncology OncoAlert Oncology Brothers @DrGattiMays Sagar Sardesai Dionisia Quiroga, DO, PhD

Great work Athira Jayan! Biomarkers to predict #IOTOX are greatly needed #ASCO24

Much talk of BICR (blinded independent central review) ASCO. cf ascopubs.org/doi/10.1200/JC… "BICRs may introduce bias because of informative censoring, which results from having to censor unconfirmed locally determined progressions." i.e. tends to overstate PFS HT Ruth O'Regan

Learning from the best! Shipra Gandhi 👏

A-BRAVE phase 3: among pts with TNBC and (mostly) RD after NACT, adjuvant avelumab for 1 year did not sign improve DFS (68.3% vs 63.2%, p=0.1) but did improve DDFS and OS (84.8% vs 76.3%, p=0.02), with low rate of AE. Impressive academic effort with extremely interesting results.

#ASCO24 Rebecca Shatsky, MD fabulous presentation of I-SPY 2 block A neoadjuvant Dato/Durva in MMP hi risk HR+ and TNBC. Hi pCR with just 4 cycles of Rx graduating in the immune + subtype. Data from addl Rx later this year! OncoAlert

Spectacular work by Kevin Kalinsky, MD, MS, FASCO showing that low serum AMH could identify which patients can safely forgo adjuvant chemo 👉🏼Awaiting validation #ASCO24 #bcsm OncoAlert

What once was a future horizon is now the present shore: HER2 ultralow is a new targetable entity. Yet we’re only halfway the navigation of the HER2 paradigm. Enhanced methods for the quantitation of HER2 & prediction of ADC activity lie ahead. Stay tuned. aacrjournals.org/cancerdiscover…

DB06 showed relevant activity with T-DXd for the 1L treatment of HER2-0 (ultralow) MBC. What about in the pretreated setting? In our large RW analysis, after a median of 3 prior lines of treatment, T-DXd showed comparable rwPFS (median 6.3-7.8 months) in HER2-low & HER2-0 MBC.

Graduated!! Honored to have completed my medical training at Roswell Park Hematology/Oncology Fellowship. Immensely grateful to my mentors, co-fellows, friends & family. Bittersweet to say bye to Roswell Park. Next stop: Breast Medical Oncology Ohio State Medical Oncology Shipra Gandhi Dharmesh Gopalakrishnan #RenukaIyer

Congratulations Arya Roy and best wishes for your #BreastOncology faculty role at OSU. We’re going to miss you!

My #ASCO24 top 5 Brest Cancer presentations and Takeaways vumedi.com/video/ascor-20…

one of the very best oncologists, mentors and colleagues - a true leader, Thanks for all you do Maryam Lustberg MD, MPH, FASCO 🙏👏! Yale Cancer Center Alliance for Clinical Trials in Oncology MASCC

Thank you ASCO for all the opportunities and collaborations over the last 2 decades #WomenInLeadership #bcsm #survonc #supponc

Starting Now: Lobular Breast Carcinoma Moderated by: Eric Winer, MD #DAVABreast

Two weeks to #ESMO24. Multiple important breast onc trials readouts across disease subtypes, including OS from KN522, DB12, 4y of NATALEE, CAPItello290, phase 1 studies of novel ADCs, IO, targeted drugs, and so much more. The countdown is on. See you soon in Barcelona! 🇪🇸 #bcsm